Financial

CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024

Financial by Comments are Disabled

MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release first quarter 2024 financial and operating results after market close on Tuesday, April 30th, 2024. The Company will host a conference call to review its results at 5:00pm Eastern Time the same day.

Continue Reading →

Cardiawave appoints Olivier Pierron as its Chief Executive Officer

Financial by 0 comments

April 16, 2024 07:24 AM Eastern Daylight Time LEVALLOIS-PERRET, France–(BUSINESS WIRE)–Cardiawave SA, a French Medtech company that has developed an innovative Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, is delighted to announce the appointment of Olivier Pierron as its new Chief Executive Officer. […]

Continue Reading →

Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™

Financial by 0 comments

JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Marizyme, Inc. (“Marizyme”, OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN) to advance the commercialization of Marizyme’s first-in-class FDA cleared product, DuraGraft™. DuraGraft™ was granted a De Novo – FDA Clearance on October 4, 2023, from the U.S. […]

Continue Reading →

Inari Medical Announces the Release of 2023 Ethos and Sustainability Report

Financial by Comments are Disabled

IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the publication of its 2023 Ethos and Sustainability Report. The report highlights Inari’s commitment to its ethos and important corresponding environmental, social and governance (ESG) initiatives. The report can be found on Inari’s website here.

Continue Reading →

Nectero Medical Announces Completion of $96M Series D Financing

Financial Peripheral/Endo by 0 comments

TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced the closing of its $96 million Series D financing round. Financing was led by Norwest Venture Partners, with large investments from Boston Scientific Corporation, BioStar Capital, Cadence Healthcare Ventures, Aphelion Capital and other firms. […]

Continue Reading →

Silk Road Medical to Report First Quarter 2024 Financial Results on April 30, 2024

Financial by Comments are Disabled

SUNNYVALE, Calif., April 09, 2024 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, April 30th, 2024. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Continue Reading →
1 … 86 87 88 89 90 … 485